Royalty Pharma Reports Second Quarter 2023 Results
August 08, 2023 07:00 ET
|
Royalty Pharma plc
Net cash provided by operating activities (GAAP) of $608 million and Adjusted Cash Receipts(1) (non-GAAP) of $545 millionAnnounced transactions of up to $1.7 billion year-to-date, including $659...
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
July 18, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023 before the U.S....
Royalty Pharma Declares Third Quarter 2023 Dividend
July 17, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, July 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2023 of $0.20 per Class A...
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023 08:15 ET
|
Royalty Pharma plc
NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 44th Annual Global Healthcare Conference on June...
Royalty Pharma Reports First Quarter 2023 Results
May 09, 2023 07:00 ET
|
Royalty Pharma plc
Net cash provided by operating activities (GAAP) of $1,034 million and Adjusted Cash Receipts(1) (non-GAAP) of $1,131 millionAnnounced transactions of up to $1.6 billion in Q1 2023, including $600...
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
May 03, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10,...
Royalty Pharma Declares Second Quarter 2023 Dividend
April 17, 2023 08:15 ET
|
Royalty Pharma plc
NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2023 of $0.20 per Class A...
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
April 13, 2023 09:01 ET
|
Royalty Pharma plc
NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023 before the U.S....
Royalty Pharma Announces $1.0 Billion Share Repurchase Program
March 27, 2023 07:30 ET
|
Royalty Pharma plc
Royalty Pharma’s founder and Chief Executive Officer, Pablo Legorreta, has also indicated that he intends to purchase up to an additional $50 million of the company’s Class A ordinary shares NEW...
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
March 23, 2023 07:00 ET
|
Royalty Pharma plc
Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholdsPureTech retains...